Stryker Corporation $SYK Shares Acquired by Tidal Investments LLC

Key Points

• Tidal Investments increased its Stryker stake by 174.2% in the second quarter, acquiring 70,805 additional shares for a total of 111,457 shares valued at approximately $35.1 million. Institutional investors collectively own 77.09% of Stryker.
• Stryker shares opened at $275.99, near the company’s one-year low, while analysts maintained a consensus “Moderate Buy” rating with an average price target of $381.40.
• Stryker reported quarterly earnings of $3.69 per share, beating estimates, with revenue rising 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, equal to a 1.3% annualized yield.

Tidal Investments LLC lifted its position in Stryker Corporation (NYSE:SYK - Free Report) by 174.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 111,457 shares of the medical technology company's stock after buying an additional 70,805 shares during the quarter. Tidal Investments LLC's holdings in Stryker were worth $35,091,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Gables Capital Management Inc. purchased a new stake in Stryker during the second quarter worth about $25,000. Kilter Group LLC purchased a new position in shares of Stryker in the second quarter valued at approximately $25,000. Highland Investment Advisors LLC acquired a new position in shares of Stryker in the second quarter valued at approximately $25,000. Cornerstone Financial Management LLC grew its holdings in shares of Stryker by 66.0% in the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after purchasing an additional 31 shares in the last quarter. Finally, Godfrey Financial Associates Inc. purchased a new stake in Stryker during the 4th quarter worth approximately $26,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda Stryker sold 300,000 shares of the business's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock valued at $118,197,701 over the last quarter. Company insiders own 4.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Citizens Jmp cut their price objective on Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a research report on Monday, August 3rd. BMO Capital Markets reissued an "outperform" rating and set a $317.00 target price on shares of Stryker in a research note on Wednesday. Wolfe Research downgraded Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. Wells Fargo & Company reduced their price target on Stryker from $418.00 to $348.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Piper Sandler decreased their price objective on Stryker from $420.00 to $390.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $381.40.

Stryker Stock Down 0.2%

Shares of NYSE SYK opened at $275.99 on Thursday. The business has a 50-day moving average of $326.77 and a two-hundred day moving average of $327.62. The company has a market capitalization of $105.86 billion, a price-to-earnings ratio of 28.60, a price-to-earnings-growth ratio of 1.73 and a beta of 0.76. Stryker Corporation has a 1 year low of $270.85 and a 1 year high of $392.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. During the same quarter in the prior year, the business posted $3.13 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts forecast that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker's principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.